OBJECTIVES: Lung cancer is the leading cause of cancer-related death in the USA. Regulatory T cells (Tregs) normally function to temper immune responses and decrease inflammation. Previous research has demonstrated different subsets of Tregs with contrasting anti- or pro-inflammatory properties. This study aimed to determine Treg subset distributions and characteristics present in non-small cell lung cancer (NSCLC) patients. METHODS: Peripheral blood was collected from healthy controls (HC) and NSCLC patients preceding surgical resection, and mononuclear cells were isolated, stained, and analyzed by flow cytometry. Tregs were defined by expression of CD4 and CD25 and classified into CD45RA(+)Foxp3(int) (naïve, Fr. I) or CD45RA(-)Foxp3(hi) (activated Fr. II). Activated conventional T cells were CD4(+)CD45RA(-)Foxp3(int) (Fr. III). RESULTS: Samples from 23 HC and 26 NSCLC patients were collected. Tregs isolated from patients with NSCLC were found to have enhanced suppressive function on naive T cells. Cancer patients had significantly increased frequencies of activated Tregs (fraction II: FrII), 17.5 versus 3.2% (P < 0.001). FrII Tregs demonstrated increased RORγt and IL17 expression and decreased IL10 expression compared to Tregs from HC, indicating pro-inflammatory characteristics. CONCLUSIONS: This study demonstrates that a novel subset of Tregs with pro-inflammatory characteristics preferentially expand in NSCLC patients. This Treg subset appears identical to previously reported pro-inflammatory Tregs in human colon cancer patients and in mouse models of polyposis. We expect the pro-inflammatory Tregs in lung cancer to contribute to the immune pathogenesis of disease and propose that targeting this Treg subset may have protective benefits in NSCLC.
OBJECTIVES:Lung cancer is the leading cause of cancer-related death in the USA. Regulatory T cells (Tregs) normally function to temper immune responses and decrease inflammation. Previous research has demonstrated different subsets of Tregs with contrasting anti- or pro-inflammatory properties. This study aimed to determine Treg subset distributions and characteristics present in non-small cell lung cancer (NSCLC) patients. METHODS: Peripheral blood was collected from healthy controls (HC) and NSCLCpatients preceding surgical resection, and mononuclear cells were isolated, stained, and analyzed by flow cytometry. Tregs were defined by expression of CD4 and CD25 and classified into CD45RA(+)Foxp3(int) (naïve, Fr. I) or CD45RA(-)Foxp3(hi) (activated Fr. II). Activated conventional T cells were CD4(+)CD45RA(-)Foxp3(int) (Fr. III). RESULTS: Samples from 23 HC and 26 NSCLCpatients were collected. Tregs isolated from patients with NSCLC were found to have enhanced suppressive function on naive T cells. Cancerpatients had significantly increased frequencies of activated Tregs (fraction II: FrII), 17.5 versus 3.2% (P < 0.001). FrII Tregs demonstrated increased RORγt and IL17 expression and decreased IL10 expression compared to Tregs from HC, indicating pro-inflammatory characteristics. CONCLUSIONS: This study demonstrates that a novel subset of Tregs with pro-inflammatory characteristics preferentially expand in NSCLCpatients. This Treg subset appears identical to previously reported pro-inflammatory Tregs in humancolon cancerpatients and in mouse models of polyposis. We expect the pro-inflammatory Tregs in lung cancer to contribute to the immune pathogenesis of disease and propose that targeting this Treg subset may have protective benefits in NSCLC.
Authors: Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie Journal: Sci Transl Med Date: 2012-12-12 Impact factor: 17.956
Authors: Kui Shin Voo; Yui-Hsi Wang; Fabio R Santori; Cesar Boggiano; Yi-Hong Wang; Kazuhiko Arima; Laura Bover; Shino Hanabuchi; Jahan Khalili; Ekaterina Marinova; Biao Zheng; Dan R Littman; Yong-Jun Liu Journal: Proc Natl Acad Sci U S A Date: 2009-03-09 Impact factor: 11.205
Authors: Elias Gounaris; Nichole R Blatner; Kristen Dennis; Fay Magnusson; Michael F Gurish; Terry B Strom; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie Journal: Cancer Res Date: 2009-07-01 Impact factor: 12.701
Authors: Harvey W Smith; Lei Yang; Chen Ling; Arlan Walsh; Victor D Martinez; Jonathan Boucher; Dongmei Zuo; Ethan S Sokol; Dean C Pavlick; Garrett M Frampton; Juliann Chmielecki; Laura M Jones; Philippe P Roux; William W Lockwood; William J Muller Journal: Proc Natl Acad Sci U S A Date: 2020-07-29 Impact factor: 11.205
Authors: Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam Journal: Mol Cancer Date: 2016-10-27 Impact factor: 27.401
Authors: J A Atzin-Méndez; J S López-González; R Báez; M C Arenas-Del Angel; L F Montaño; D Silva-Adaya; R Lascurain; P Gorocica Journal: Oncol Rep Date: 2015-10-13 Impact factor: 3.906